During Q4, the company billed 11,789 tissue-based units and 12,036 liquid-based units, representing growth of 50% and 10%, respectively. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Disclaimer & DisclosureReport an Issue
